- Pattern Computer has received positive national lab results for combination 
therapy drug candidates targeting basal-like breast cancer

Pattern Computer(R), Inc. ( 
https://c212.net/c/link/?t=0&l=en&o=2772580-1&h=1563465989&u=http%3A%2F%2Fwww.patterncomputer.com%2F&a=Pattern+Computer%C2%AE%2C+Inc. 
) has received confirmation from Lawrence Berkeley National Laboratory that 
drug therapy combinations it identified using its proprietary machine learning 
pattern discovery system are effective in killing malignant breast cancer 
tumors. Notably, the Pattern Computer team chose to go after basal-like or 
"triple negative" breast cancer because it represents 15-20% of breast cancer 
patients, is aggressive, and has no effective drugs available. For further 
technical detail, go to https://www.patterncomputer.com/news/lbnl/.

Logo - https://mma.prnewswire.com/media/1143036/Pattern_Computer_Logo.jpg 

"We're very excited by the two-tier bio-validation results we've just received 
for our combination therapy candidates, which we filtered for drugs that were 
already individually FDA-approved or in process. This was our first project in 
biotech, and we are hopeful for many future successes along the path to 
developing a treatment for this and other cancers and diseases," said Mark R. 
Anderson, CEO of Pattern Computer.

The two therapy treatments successfully completed final in vitro organoid 
testing at Lawrence Berkeley National Laboratory, demonstrating "significant 
synergistic interaction" in killing malignant tumor cells, with statistically 
"low-to-no adverse effects" on healthy cells. With these results, Pattern 
Computer will proceed to the next phase of preclinical testing.

"We appreciate our results are still relatively early; we're therefore 
approaching these next steps with due care and caution," Anderson said, "but 
we're encouraged by the biological validation we are seeing to date of our 
computational models in this area. We are delighted to be working with Lawrence 
Berkeley National Labs on confirming these findings." 

Pattern Computer, a Seattle-area startup, uses its proprietary Pattern 
Discovery Engine (TM) to solve the most important and intractable problems in 
business and medicine. The company's proprietary mathematical techniques can 
find complex patterns in very high-order data which have eluded detection by 
much larger systems. 

While the company is currently applying its computational platform to the 
challenging field of drug discovery, it is also making pattern discoveries for 
partners in several other sectors, including additional biomedical research, 
materials science, aerospace manufacturing, veterinary medicine, air traffic 
operations, and finance.

FOR CUSTOMERS AND PARTNERS, CONTACT:        
Nick Psyhogeos                              
+1-425-829-0467	                            
inquiry@patterncomputer.com;                 

FOR INTERVIEWS, CONTACT:
Denyse Hudson
+1-360-298-0658
denyse@patterncomputer.com 

SOURCE: Pattern Computer